Trilostane

• CAT Number: A000679
• CAS Number: 13647-35-3
• Molecular Formula: C20H27NO3
• Molecular Weight: 329.40
• Purity: ≥95%
• Synonyms: 13647-35-3; Vetoryl; Trilostanum; Desopan; Trilostano
• Target: Dehydrogenase
• Solubility: >16.4mg/mL in DMSO
• Storage: -20°C
• IUPAC Name: (1S,2R,6R,8S,11S,12S,15S,16S)-5,15-dihydroxy-2,16-dimethyl-7-oxapentacyclo[9.7.0.02,8.06,8.012,16]octadec-4-ene-4-carbonitrile
• InChI: InChI=1S/C20H27NO3/c1-18-7-6-14-12(13(18)3-4-15(18)22)5-8-20-17(24-20)16(23)11(10-21)9-19(14,20)2/h12-15,17,22-23H,3-9H2,1-2H3/t12-,13-,14-,15-,17+,18-,19+,20+/m0/s1
• InChIKey: KVJXBPDAXMEYOA-CXANFOAXSA-N
• SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CC[C@]45[C@@]3(CC(=C([C@H]4O5)O)C#N)C

Trilostane（Cat No.:A000679）is a synthetic steroidogenesis inhibitor with the molecular formula C20H27NO3, primarily used to treat Cushing’s disease and hyperadrenocorticism in veterinary medicine, especially in dogs. It works by inhibiting 3β-hydroxysteroid dehydrogenase, an enzyme crucial for cortisol and aldosterone synthesis in the adrenal cortex. This leads to reduced production of glucocorticoids and mineralocorticoids. Trilostane is administered orally and has shown effectiveness in managing adrenal hormone-related disorders. It may also be studied for potential human applications, including breast cancer treatment. Common side effects include lethargy, vomiting, and electrolyte imbalances, requiring regular monitoring.